Assessment of hepatic steatosis by controlled attenuation parameter using the M and XL probes: an individual patient data meta-analysis

The Lancet Gastroenterology & Hepatology

Fecha de publicación: 15 de enero de 2021

DOI: https://doi.org/10.1016/S2468-1253(20)30357-5

Autores: David Petroff, PhD ^†, Valentin Blank, MD ^†, Prof Philip N Newsome, PhD, ShalimarMD, Cosmin Sebastian Voican, PhD, Maja Thiele, PhD, Prof Victor de Lédinghen, MD, Stephan Baumeler, MD, Prof Wah Kheong Chan, PhD, Prof Gabriel Perlemuter, MD, Ana-Carolina Cardoso, MD, Prof Sandeep Aggarwal, MD, Magali Sasso, PhD, Peter J Eddowes, MD, Michael Allison, MD, Prof Emmanuel Tsochatzis, PhD, Prof Quentin M Anstee, MD, David Sheridan, MD, Jeremy F Cobbold, PhD, Prof Sylvie Naveau, MD, Monica Lupsor-Platon, MD, Prof Sebastian Mueller, MD, Prof Aleksander Krag, PhD, Marie Irles-Depe, MD, David Semela, MD, Prof Grace Lai-Hung Wong, MD, Prof Vincent Wai-Sun Wong, MD, Prof Cristiane A Villela-Nogueira, MD, Harshit Garg, MD, Prof Olivier Chazouillères, MD, Johannes Wiegand, MD, Thomas Karlas, MD 

Background: Diagnostic tools for liver disease can now include estimation of the grade of hepatic steatosis (S0 to S3). Controlled attenuation parameter (CAP) is a non-invasive method for assessing hepatic steatosis that has become available for patients who are obese (FibroScan XL probe), but a consensus has not yet been reached regarding cutoffs and its diagnostic performance. We aimed to assess diagnostic properties and identify relevant covariates with use of an individual patient data meta-analysis.

Leer más